Valuation: Cyclopharm Limited

Market Cap 64.29M 44.64M 39.05M 36.01M 33.32M 63.24M 4.26B 431M 169M 2.09B 168M 164M 7.25B P/E 2026 *
-3.4x
P/E 2027 * -7.29x
Enterprise Value 64.29M 44.64M 39.05M 36.01M 33.32M 63.24M 4.26B 431M 169M 2.09B 168M 164M 7.25B EV / Sales 2026 *
1.76x
EV / Sales 2027 * 1.39x
Free-Float
58.35%
Yield 2026 *
-
Yield 2027 * -
1 day+10.87%
1 week+2.00%
Current month+8.51%
1 month-19.05%
3 months-37.42%
6 months-48.48%
Current year-47.96%
1 week 0.46
Extreme 0.46
0.52
1 month 0.45
Extreme 0.45
0.6
Current year 0.45
Extreme 0.45
1.29
1 year 0.45
Extreme 0.45
1.29
3 years 0.45
Extreme 0.45
3.15
5 years 0.45
Extreme 0.45
3.15
10 years 0.45
Extreme 0.45
3.45
Manager TitleAgeSince
Chief Executive Officer 60 2009-10-20
Director of Finance/CFO - 2024-02-25
Chief Operating Officer - 2016-12-31
Director TitleAgeSince
Director/Board Member 65 2021-08-09
Director/Board Member 60 2008-06-02
Director/Board Member - 2022-08-31
Date Insider Type Main position Quantity % Market Cap.
03-11Buy

Director

21,052 0.0175%
03-11Buy

Chief Executive Officer

10,526 0.0087%
03-11Buy

Director

5,263 0.0044%
Change 5-day change 1-year change 3-year change Capi.($)
+10.87%+2.00%-50.96%-75.71% 40.08M
+2.51%-0.42%+24.14%+0.85% 190B
-0.82%-2.93%-21.70%+21.53% 147B
+2.53%-1.49%-2.98%-16.84% 135B
+0.06%-0.72%-56.47%-14.96% 66.6B
-2.18%-2.88%+18.74%+0.02% 53.92B
+0.38%-1.66%-27.47%-30.84% 43.57B
+3.08%+1.32%+9.16%+11.87% 36.45B
+2.26%-0.88%+7.66%+42.05% 36.15B
+1.00%-0.76%-18.73%-3.96% 29.69B
Average +1.98%+0.29%-11.86%-6.60% 73.8B
Weighted average by Cap. +1.11%+1.62%-3.94%+0.74%

Financials

2026 *2027 *
Net sales 36.6M 25.41M 22.23M 20.5M 18.97M 36M 2.43B 245M 96.23M 1.19B 95.39M 93.33M 4.13B 46.2M 32.07M 28.06M 25.87M 23.94M 45.44M 3.06B 310M 121M 1.5B 120M 118M 5.21B
Net income -18.9M -13.12M -11.48M -10.59M -9.79M -18.59M -1.25B -127M -49.69M -615M -49.26M -48.19M -2.13B -9.9M -6.87M -6.01M -5.54M -5.13M -9.74M -656M -66.4M -26.03M -322M -25.8M -25.24M -1.12B
Net Debt - -
Logo Cyclopharm Limited
Cyclopharm Limited is an Australia-based radiopharmaceutical company. The Company's principal activity is engaged in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development and distribution of third-party products to the diagnostic imaging sector. Its Technegas product is a broad-spectrum diagnostic lung imaging technology for visualization of pulmonary ventilation and lung function. It includes the sale of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. The Company uses Technegas technology, which is a structured ultra-fine dispersion of radioactive labelled carbon, produced by using driedTechnetium-99m in a carbon crucible. Company distributes its products in approximately 65 countries.
Employees
109
Date Price Change Volume
26-07-09 A$0.5100 +10.87% 2,596
26-07-08 A$0.4600 0.00% 267,413
26-07-07 A$0.4600 -3.16% 53,651
26-07-06 A$0.4750 -4.04% 81,775
26-07-03 A$0.4950 -1.00% 35,542
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.3541USD
Average target price
0.6940USD
Spread / Average Target
+96.01%

Quarterly revenue - Rate of surprise